Relative vaccine effectiveness against COVID-19 hospitalisation in persons agedâ¯≥â¯65â¯years: results from a VEBIS network, Europe, October 2021 to July 2023.
Euro Surveill
; 29(1)2024 01.
Article
em En
| MEDLINE
| ID: mdl-38179626
ABSTRACT
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12â¯weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
COVID-19
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article